The use of “Acellbia” – a biosimilar of rituximab in systemic sclerosis
Introduction. The possibilities of modern therapy for systemic sclerosis (SSc) remains limited, since most of the used drugs do not have a diseasemodifying effect. This encourages the study of new approaches that potentially affect the fundamental pathological processes underlying the disease. One e...
Bewaard in:
| Hoofdauteurs: | , , , , , , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Russo |
| Gepubliceerd in: |
IMA PRESS LLC
2023-08-01
|
| Reeks: | Научно-практическая ревматология |
| Onderwerpen: | |
| Online toegang: | https://rsp.mediar-press.net/rsp/article/view/3403 |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|